Background {#Sec1}
==========

There is an increasing use of economic evaluation in healthcare to inform medical decision making. Drummond et al. \[[@CR1]\] defined economic evaluation in healthcare as "the comparison of alternative options in terms of their costs and consequences". Economic evaluations are important in decisions about investment in modern technologies and for the rational choices between different treatment options. Cost-effectiveness studies of cancer in general and localized prostate cancer in particular is important because it helps patients, physicians, and policymakers make quantitatively-based decisions, which balance treatment efficacy, toxicity, and costs. Cost-effectiveness analysis allows for quantitative comparison of different treatments for the same condition and allows one to weigh the difference in costs between two or more treatment options against the difference in effectiveness. Cost-effectiveness research of localized prostate cancer treatments can have a significant impact on healthcare spending due to the high prevalence of prostate cancer and the many treatment options with similar outcomes, yet substantially different costs. Therefore, cost-effectiveness studies for localized prostate cancer are paramount as they may save the health care system millions of dollars while optimizing the value of care delivered to patients.

Prostate cancer is the most common cancer in men worldwide. It is the most common malignancy diseases in males in Europe and North America. The American Cancer Society estimated 164,690 new cases of prostate cancer, with 29,430 prostate cancer-related diseases in the United States by the year 2018 \[[@CR2]\]. It is the most common neoplasm among men and third-ranked cause of cancer death in Europe, with almost 400,000 cases and over 92,000 deaths \[[@CR3]\]. In England and Wales each year there are about 27,773 new cases and 9161 deaths \[[@CR4]\]. More than half of the men diagnosed with prostate cancer in the UK each year are aged 70 and over. The economic impact of prostate cancer in an aging population is expected to be high due to the high prevalence of prostate cancer. In the UK the mean direct costs per patient for initial treatment for prostate cancer have been estimated at around £2505. This figure compares to £2572 in Spain, £3205 in Germany, £4129 in Italy, and £4622 in France \[[@CR4]\]. The total estimated costs for all patients in the first year from diagnosis were estimated to be £94.1 million in the UK compared to £92.5, £196.9, £163.0 and £310.6 million in the other countries respectively \[[@CR4]\].

Localized prostate cancer (stage 1 and 2) is the stage in which the cancer is only in the prostate and has not spread anywhere else in the body. Radiotherapy is a recommended treatment option for clinically localized prostate cancer. It involves using high energy rays or particles to kill cancer cells. External beam radiotherapy (EBRT) is the modern types of radiotherapy for prostate cancer. In EBRT, beams of radiation are focused on the prostate gland from a machine outside the body. The four-modern external beam radiation therapies for prostate cancer include three-dimensional conformal radiation therapy (3D-CRT), intensity modulated radiation therapy (IMRT), stereotactic body radiation therapy (SBRT) and proton beam radiation therapy (PBR). Radiation oncology is the most expensive treatment option for cancer \[[@CR5], [@CR6]\]. Several studies indicated that most treatment costs of cancer were dominated by direct medical costs of radiation therapy. Its total costs is also increased through time due to high demand \[[@CR5]--[@CR7]\]. Therefore, economic evaluation of such expensive treatment option is needed to minimize cost and to meet the current demand of the treatment.

The objective of this systematic review was to assess and identify studies that examined model-based economic evaluation of external beam radiation therapy for the treatment of localized prostate cancer.

Methods {#Sec2}
=======

Search strategy {#Sec3}
---------------

A systematic review of the published literature was conducted in the period between November 2017 and January 2018 by the first author through PubMed, NHS EED (NHS Economic Evaluation Database, CRD York), and Cochrane databases using a specific search strategy (see Additional file [1](#MOESM1){ref-type="media"}: Appendix S1). The literatures were searched according to the preferred reporting items for systematic reviews and meta-analyses (PRISMA) statement \[[@CR8]\]. At first, the author identified 1046 citations from all the databases. From PubMed 840 citations were identified using the term 'cost--benefit analysis', cost-effectiveness analysis', 'cost-utility analysis' and 'prostate cancer'. The similar search strategy was used for Cochrane and 79 citations were extracted. For NHS EED the term 'prostate cancer' was used to extract 127 citations. The extracted citations were imported into the Rayyan systematic review site \[[@CR9]\] for inclusion or exclusion based on the defined criteria as described below. Studies included in this review were articles published between 2003 and 2017, and that conducted full-economic evaluations of the modality of external beam radiotherapy for the treatment of localized prostate cancer. Finally, 12 articles were selected for full review and included in the qualitative synthesis.

Inclusion criteria {#Sec4}
------------------

The target population includes men with prostate cancer, i.e., localized prostate cancer. Target studies focussed on full economic evaluations of prostate cancer (includes cost-effectiveness analysis, cost--benefit analysis, and cost-utility analysis). Modeling approaches based on decision trees, Markov cohort models, state-transition microsimulation models, and mathematical equations, in line with the definition of a "model" given by the "ISPOR Task Force on Good Research Practices---Modelling Studies" \[[@CR10]\]. Only articles published in the English language is considered in this review. For the details of the inclusion criteria and patient intervention comparator outcome (PICO) strategy is presented in Additional file [1](#MOESM1){ref-type="media"}: Appendix S2.

Exclusion criteria {#Sec5}
------------------

Studies that are not full economic evaluations and studies that focus on diagnosis and screening of prostate cancer were excluded from the review. Abstracts were excluded if the source was a letter, editorial, review, commentary, methodological paper, abstracts without providing full information about the model and studies using models only as an illustration.

Results {#Sec6}
=======

Figure [1](#Fig1){ref-type="fig"} shows the preferred reporting items for systematic reviews and meta-analyses diagram \[[@CR8]\]. After duplicates were removed, 921 abstracts were screened. Of these, 643 articles were excluded and 278 full articles were assessed for eligibility.Fig. 1PRISMA 2009 flow diagram for model-based economic evaluations for localized prostate cancer \[[@CR3]\]

Summary of analytic framework, model features, methods and findings of included studies {#Sec7}
---------------------------------------------------------------------------------------

Table [1](#Tab1){ref-type="table"} presents cost-effectiveness studies with full economic evaluations that compared IMRT with 3D-CRT for prostate cancer treatment. There are eight studies identified in this group and the year of the studies were from 2005 to 2016.Table 1Cost-effectiveness analyses comparing IMRT and 3D-CRT for prostate cancerStudy (authors, year)Target population risk groupTime horizon/cycle lengthPerspective/countryData sourcesDiscount rate for costs and outcomesModel type/type of evaluation/sensitivity analysisEffectiveness dataCost data/yearCarter et al. (2014) \[[@CR11]\]Hypothetical cohort of 65 years patients receiving radiotherapy to the prostate bed20 years/1 year3rd party payer perspective/AustraliaLiterature sources and their clinical interpretation, expert opinionsLiterature sources, AR-DRG cost weights, medicare benefits schedule, pharmaceutical benefits scheduleAnnual discount rate of 5% was used for costs and outcomesMarkov model/cost-utility analysis/one-way and probabilistic sensitivity analysisHummel et al. (2012) \[[@CR12]\]70-year-old-man with well-differentiated tumorLifetime/NAPayer NHS/UKSystematic literature reviewSingle-centre hospital costs, literature sources, expert opinion/2008Costs and QALYs were discounted at a rate of 3.5% per yearDiscrete event simulation model/cost-utility analysis/one-way and probabilistic sensitivity analysisKonski et al. (2005) \[[@CR13]\]70-year-old man with a good and intermediate-risk prostate cancer10 yearsPayer US medicareAdministrative data: billing department at the Fox Chase Cancer CenterMedicare insuranceMarkov modelKonski et al. (2006) \[[@CR14]\]70-year-old intermediate risk patients15 years/1 year3rd payer medicare perspective/USLiterature sourcesLiterature sources, drug red book/2005Cost and benefits were discounted at 3% per yearMarkov model/cost-utility analysis/probabilistic sensitivity analysisYong et al. (2012) \[[@CR15]\]Cohort of 70-year-old men with localized prostate cancerLifetime/1 monthHealth system perspective/CanadaLiterature sourcesActivity-based costing, Ontario physician fee schedule, OCCI ambulatory care Ontario laboratory fee schedule, literature sources, drug formularies/20095% discount rate was used to adjust costs and quality-adjusted life-yearsMarkov model/cost-utility analysis/one-way sensitivity analysisCooperberg et al. (2013) \[[@CR16]\]Men aged 65 years old with low-risk, intermediate-risk, or high-risk prostate cancerLifetimePayer US medicareLiterature reviewMedicare cost dataCosts and QALY were discounted at 3% annuallyMarkov modelZemplenyi et al. (2016) \[[@CR17]\]Low-, mid, and high-risk patients with localized prostate cancer10 years/1 month3rd party payer perspective/HungaryLiterature sources (three retrospective cohort studies and two RCTs)Single-center cost collection study (micro-costing)Costs and the quality-adjusted life years were discounted at a rate of 3.7% per yearMarkov model cost-utility analysis/one-way and probabilistic sensitivity analysis, subgroup analysis

Most of the studies analyzed the cost effectiveness analysis for localized prostate cancer for patients aged 65 years old and above. The time horizon of the model for the studies were ranges from 10 years \[[@CR13], [@CR17]\], 15 years \[[@CR14]\], 20 years \[[@CR11]\] to lifetime \[[@CR12], [@CR15], [@CR16]\]. Most of the papers report cost data from the payer's perspective. There were no studies analyzed cost data from the hospital or societal perspective. All the studies were conducted in five different countries including four studies in US from the payer perspective \[[@CR13], [@CR14], [@CR16]\]; Canada \[[@CR15]\]; Australia \[[@CR11]\]; UK \[[@CR12]\] and Hungary \[[@CR17]\].

For most of the studies the source of the effectiveness data is from published literature. The studies used a variety of sources for cost data including literature sources, AR-DRG cost weights, Medicare Benefits Schedule, Pharmaceutical Benefits Schedule, Medicare and Medicaid service was the main cost data sources for most of the US studies.

All the studies were full-economic evaluations using a Markov model \[[@CR11], [@CR13]--[@CR17]\]. Carter et al. \[[@CR11]\] estimated the cost effectiveness of IMRT compared to 3D-CRT using a Markov decision model by calculating the incremental quality adjusted life years (QALYs) and costs from the perspective of the Australian healthcare system. The study used a hypothetical cohort of 65 years old patients receiving radiotherapy to the prostate bed. A 20 years-time horizon with a 1-year cycle was used.

Using a discrete event simulation model, Hummel et al. \[[@CR12]\] assessed cost-effectiveness from a UK National Health Service perspective.

Konski et al. \[[@CR13]\] modelled a 70 year old population with a low and intermediate-risk prostate cancer. Cost analysis was performed from US Medicare payer's perspective by taking cost data for men with Medicare insurance and prostate cancer treated with IMRT and 3D-CRT obtained from the billing department at the Fox Chase Cancer Center \[[@CR13]\]. By another study Konski et al. \[[@CR14]\] also discussed the cost-effectiveness of IMRT and 3D-CRT for a 70-year-old intermediate risk patients for a time horizon of 15 years using a Markov model. The model simulated four different health states including posttreatment, hormone therapy, chemotherapy, and death. The difference between the studies Konski et al. \[[@CR13]\] and Konski et al. \[[@CR14]\] is that the first study used a time horizon of 10 years and the latter use 15 years.

Yong et al. \[[@CR15]\], the study used a clinical effectiveness estimates from a systematic review. At the base case analysis, the study assumed equal biochemical survival for IMRT and 3D-CRT, but lower frequency of gastrointestinal toxicity for IMRT. The cost data were estimated through activity-based costing, incorporating input from radiation oncologists, physicists and treatment planners from the Australian health care payer's perspective \[[@CR15]\]. The authors developed a life time Markov model with a cycle length of 1 month to compare the cost effectiveness of IMRT with 3D-CRT for men with clinically localized prostate cancer. The model includes six health states. The study conducted one-way sensitivity analyses to verify the logical consistency of the model and to assess the robustness of the model results by evaluating the cost-effectiveness of IMRT from different scenarios.

Cooperberg et al. \[[@CR16]\] analyzed the cost effectiveness of different treatment options including radical prostatectomy and radiation therapy options for the treatment of three groups of patients risk patients i.e. men aged 65 years old with low-risk, intermediate-risk, or high-risk prostate cancer. The study used a lifetime Markov model to model a hypothetical man with low-, intermediate-, and high-risk prostate cancer over their lifetimes following primary treatment. The data for probabilities of outcomes were based on a systematic review. The study assumed that patients could experience remission, recurrence, salvage treatment, metastasis, death from prostate cancer, and death from other causes. Costs were determined from the US payer perspective, with incorporation of patient costs in a sensitivity analysis \[[@CR16]\].

Zemplenyi et al. \[[@CR17]\], the study used a Markov model with 10 years of time horizon and 1-month cycle length to calculate the incremental quality-adjusted life years and costs. The data for transition probabilities, adverse events and utilities were derived from relevant systematic reviews. The study used a cost data from a large university hospital and the cost analysis was done from the perspective of Hungarian third-party payer.

As shown in Table [2](#Tab2){ref-type="table"}, there is one article comparing three external beam radiotherapy for prostate cancer \[[@CR18]\]. Parthan et al. \[[@CR18]\] analysed the cost effectiveness of three external beam radiation treatment modalities for the treatment of localized prostate cancer. These modalities were SBRT, IMRT and PBT. The study used a life time Markov cohort decision model for 65-year-old men with localized prostate cancer. The model incorporated the probabilities of experiencing treatment-related long-term toxicity or death with different possible disease states including all possible combinations of GI, genitourinary, sexual toxicity, and death. The study took toxicity probabilities from sources using meta-analytical techniques. The data for utilities and costs were taken from publicly available secondary sources (2011 Medicare reimbursements rates). The study calculated quality-adjusted life expectancy and expected lifetime cost per patient. The cost analysis was performed from both payer and societal perspectives by including lost work time during radiation treatment at 2011 wage rates estimated from the Bureau of Labor Statistics. One-way and probabilistic sensitivity analyses were per-formed.Table 2Cost-effectiveness analyses comparing IMRT, SBRT and PBT for localized prostate cancer treatmentStudy (authors, year)Target population risk groupTime horizon/cycle lengthInterventions comparedPerspective/countryData sourcesDiscount rate for costs and outcomesModel type/type of evaluation/sensitivity analysisEffectiveness dataCost data/yearParthan et al. (2012) \[[@CR18]\]65-year-old men with localized prostate cancerLifetime/not reportedSBRT vs. IMRT vs. PBT3rd party Medicare payer and societal perspective/USPublished sources, meta-analytical techniquesMedicare rates, Bureau of Labour Statistic, literature sources, Red Book/2011Costs and utilities discounted at 3.0% annuallyMarkov model/cost-utility analysis/one-way deterministic and probabilistic sensitivity analysisHodges et al. (2012) \[[@CR19]\]70-year-old low-to intermediate-risk patient with confined prostate cancer10 years/1 yearIMRT vs SBRT3rd party medicare payer perspective/USLiterature sourcesLiterature sources, medicare allowable costs, ambulatory payment classification/2010Costs and utilities were discounted at a rate of 3% per yearMarkov model/cost-utility analysis/probabilistic sensitivity analysisSher et al. (2014) \[[@CR20]\]65-year-old men with low-risk prostate cancerLifetime/4 monthsIMRT vs. robotic and non-robotic SBRT3rd party medicare payer perspective/USLiterature sourcesMedicare payment schedule for hospital-based practice/2012Markov model/cost-utility analysis/one-way deterministic and probabilistic sensitivity analysisLundkvist et al. (2005) \[[@CR21]\]Theoretical cohort age: 65-yearLifetimeIMRT vs PBTSocietal SwedenLiterature sourcesLiterature sourcesCosts and effects were discounted with 3% annually.Markov model cost-utility analysisKonski et al. (2007) \[[@CR22]\]Men aged 60 or 70 years old with intermediate-risk prostate cancerNAIMRT vs PBTpayer US medicareliteratureliterature and from patient interviewsCosts and effects were discounted with 3% annuallyMarkov model

There are two articles comparing IMRT with SBRT \[[@CR19], [@CR20]\]. Hodges et al. \[[@CR19]\] used a Markov decision model to simulate four disease states after radiation which could influence costs (no evidence of disease, hormone-responsive progression, hormone-refractory progression requiring chemotherapy, and death). The time horizon for the model was 10 years with 1-year cycles. The study took third party Medicare payer perspective using 2010 Medicare reimbursements rates. The study used effectiveness data from published literature. Sher et al. \[[@CR20]\] modeled the cost-effectiveness of IMRT and robotic and non-robotic SBRT for 65-year-old men with low-risk prostate cancer. The authors constructed a lifetime Markov model with a life cycle of 4 months. The study was conducted in US from the third-party Medicare payer perspective using 2012 Medicare reimbursements. Disease, treatment, and toxicity data were extracted from the literature. The study performed both deterministic and probabilistic sensitivity analyses (PSA) were performed over a wide range of potential parameters.

On the other hand, there are two studies compared IMRT with PBT \[[@CR21], [@CR22]\]. Lundkvist et al. \[[@CR21]\] assessed the cost-effectiveness of proton therapy in the treatment of four different cancers: left-sided breast cancer, prostate cancer, head and neck cancer, and childhood medulloblastoma. The study used a Markov cohort simulation model to simulate each cancer type and the life of patients treated with radiation. Cost and quality adjusted life years (QALYs) were used as primary outcome measures. The study calculated costs from a societal perspective in Sweden.

Konski et al. \[[@CR22]\] used Markov model to incorporate health states of post-treatment, disease progression hormonally responsive (hormone therapy), disease progression hormonally unresponsive (chemotherapy), and death. The study assume that patients spend 1 year in each state before the opportunity to transition to another state or to stay in the same state.

Main findings of economic evaluations identified in the systematic reviews {#Sec8}
--------------------------------------------------------------------------

Table [3](#Tab3){ref-type="table"} shows the main findings of the cost effectiveness studies that compared IMRT with 3D-CRT.Table 3Main findings of Cost-effectiveness studies comparing IMRT and 3D-CRT for localized prostate cancerStudy (authors, year)ResultsConclusionsMean costQALYsICERCarter et al. (2014) \[[@CR11]\]After 5 yearsIMRT: \$99323D-CRT: \$9706After 20 yearsIMRT: \$32,8163D-CRT: \$ 33,917After 5 yearsIMRT: 4.2443D-CRT: 4.239After 20 yearsIMRT: 10.0793D-CRT: 10.060\$41,572/QALYIMRT is dominantIMRT was estimated to have a modest long-term advantage over 3D-CRT in terms of both improved effectiveness and reduced costHummel et al. (2012) \[[@CR12]\]Scenario 1IMRT: £61733D-CRT: £5184Scenario 2IMRT: £49463D-CRT: £4214Scenario 3IMRT: £49463D-CRT: £4486Scenario 4IMRT: £56873D-CRT: £7489Scenario 1IMRT: 6.8023D-CRT: 6.792Scenario 2IMRT: 7.0703D-CRT: 7.046Scenario 3IMRT: 7.0703D-CRT: 6.983Scenario 4IMRT: 7.0153D-CRT: 6.402Scenario 1: £104,066/QALYScenario 2: £31,162/QALYScenario 3: £5295/QALYScenario 4: dominant strategyIf IMRT can be used to prolong survival, it is very cost-effective. Otherwise, cost-effectiveness is uncertainKonski et al. (2005) \[[@CR13]\]70 years old with intermediate riskIMRT: \$33,8373D-CRT: \$21,37770 years old with good riskIMRT: \$31,9503D-CRT: \$19,21370 years old with intermediate riskUS\$16,182/QALY70 years old with good riskUS\$17,448/QALYIntensity-modulated radiation therapy was found to be cost effective in the treatment of 70 years old man with prostate cancerKonski et al. (2006) \[[@CR14]\]3D-CRT: \$21,865IMRT: \$47,9313D-CRT: 6.27IMRT: 5.62\$40,101/QALYIMRT therapy was found to be cost-effective at the upper limits of acceptabilityYong et al. (2012) \[[@CR15]\]3D-CRT\$13,501IMRT\$14,5203D-CRT: 6.062IMRT: 6.085\$26,768/QALYFor radical radiation treatment of prostate cancer, IMRT seems to be cost-effective when compared with an equivalent dose of 3D-CRTCooperberg (2013) \[[@CR16]\]IMRT: \$37,7183D-CRT: \$27,636IMRT: 9.63D-CRT: 10.3Not calculatedIMRT was found to be cost effective with a 0.5 QALYs gainedZemplenyi et al. (2016) \[[@CR17]\]3D-CRT: €7160IMRT: €6831HF-IMRT:€ 6.0193D-CRT: €5.753IMRT: €5.956HF-IMRT: €5.9573D-CRT dominated IMRTCompared to 3D-CRT, both IMRT and HF-IMRT resulted in more health gains at a lower cost

Carter et al. \[[@CR11]\] found that IMRT was dominant strategy i.e. both more effective and less costly than 3DCRT over 20 years. After 20 years the model estimated a cost for IMRT is \$32,816 and for 3D-CRT it was \$33,917. The estimated QALYs for the IMRT and 3D-CRT were 10.079 and 10.060 respectively. This showed an additional 20 QALYs gained and over \$1.1 million saved per 1000 patients treated over 20 years. The authors performed a one-way sensitivity analysis and showed that the model was highly robust to changes in individual parameters and IMRT remained the dominant treatment in all scenarios. For the probabilistic sensitivity analysis, the authors also showed that IMRT had an 86% probability of being dominant and a 93% probability of being a cost-effective treatment given an ICER threshold of \$50,000 per QALY.

On the other study Hummel et al. \[[@CR12]\] the authors used different scenarios to analyses the cost effectiveness of IMRT vs 3DCRT strategies. In scenarios where, estimated survival was greater for IMRT than 3DCRT, IMRT was clearly cost-effective (ICER \< £20,000). For scenarios where only, a difference in late gastrointestinal (GI) toxicity was assumed, the ICER was highly sensitive to uncertain model parameters, including the magnitude of the difference, the duration of gastrointestinal toxicity and the cost difference between treatments. For the most likely scenario, a 15% difference in late gastrointestinal toxicity, the ICER was £35,000, with a 20% probability that it is cost-effective at a maximum threshold of £20,000 and a 48% probability at a threshold of £30,000 \[[@CR12]\]. The authors performed a univariate sensitivity analyses on key parameters, such as age, incremental cost of IMRT in comparison with 3D-CRT, and duration of late GI toxicity. Finally, the authors concluded that IMRT was used to prolong survival and it is cost-effective.

In the findings of Konski et al. \[[@CR13]\], IMRT was also found to be cost effective in the treatment of a 70 year old man with prostate cancer. The incremental cost-effectiveness ratio of US\$16,182/QALY for men with intermediate-risk prostate cancer and US\$17,448/QALYs for men with good-risk prostate cancer. The authors also performed a sensitivity analysis and found that a longer time horizon and younger age affected the cost-effectiveness ratio. A similar study by Konski et al. \[[@CR14]\] found that the mean cost of IMRT and 3D-CRT were \$47,931 and \$21,865 respectively. The estimated amount of QALY for IMRT and 3D-CRT were 6.27 and 5.62. The incremental cost-effectiveness comparing IMRT with 3D-CRT was \$40,101/QALYs. Cost-effectiveness acceptability curve analysis revealed a 55.1% probability of IMRT being cost-effective at a \$50,000/QALY willingness to pay. Konski et al. \[[@CR14]\] concluded that IMRT was found to be cost-effective at this upper limits cost effectiveness acceptability curve. The results, however are dependent on the assumptions of improved biochemical disease-free survival with fewer patients undergoing subsequent salvage therapy and improved quality of life after the treatment. The authors suggested that in the absence of prospective randomized trials, decision analysis can help inform physicians and health policy experts on the cost-effectiveness of emerging technologies \[[@CR14]\].

The result of a study by Yong et al. \[[@CR15]\] found that the mean cost for IMRT and 3D-CRT was \$14,520 and \$13,501 with a QALY 6.085 and 6.062 respectively. IMRT produced 0.023 more QALY than 3D-CRT at an additional cost of \$621 (QALY and costs discounted at 5% per year), yielding an incremental cost-effectiveness ratio of \$26,768 per QALY gained. The treatment cost of IMRT was \$1019 more than 3D-CRT, but IMRT resulted in less frequent gastrointestinal toxicity, thus avoiding \$402 in the treatment of toxicity. In the scenario that compared a higher dose of IMRT (75.6 Gy) to 3D-CRT (68.4 Gy), IMRT improved disease control with equal toxicity incidence, and the IMRT strategy dominated (less costly and more effective). In the base case scenario (no survival difference), the cost-effectiveness of IMRT was most sensitive to the treatment cost difference between IMRT and 3DCRT.

Cooperberg \[[@CR16]\] studied the cost effectiveness of different surgical techniques and radiotherapy options including dose-escalated 3D-CRT, IMRT, brachytherapy, or combination using a life time Markov model for hypothetical men with low-, intermediate-, and high-risk prostate cancer. In the case for patients with low risk prostate cancer the study found that the mean life time cost for IMRT was \$37,718 and for 3D-CRT \$27,636. The associated QALY for IMRT and 3D-CRT were 9.6 and 10.3. Therefore, in this study IMRT was found to be cost effective for patients with low risk prostate cancer.

Zemplenyi et al. \[[@CR17]\] compared the cost-effectiveness of high-dose IMRT and hypo fractionated IMRT versus conventional dose 3D-CRT for the treatment of localised prostate cancer. The study found the expected mean lifetime cost for 3DCRT, IMRT and hypo fractionated IMRT were 7160 euros, 6831 euros and 6019 euros respectively. The expected quality-adjusted life years (QALYs) were 5.753 for 3DCRT, 5.956 for IMRT and 5.957 for HFIMRT. The study concluded that compared to 3DCRT, both IMRT and hypo fractionated IMRT resulted in more health gains at a lower cost.

Table [4](#Tab4){ref-type="table"} presents the main findings for cost-effectiveness studies of IMRT, SBRT and PBT for localized prostate cancer. The cost effectiveness analysis result by Hodges et al. \[[@CR19]\] revealed that the mean cost of SBRT was US\$22,152 with 7.9 QALYs. However, the mean cost for IMRT was US\$35,431 and 7.9 QALYs, respectively. ICER was not calculated for this analysis because of the QALYs were the same for both SBRT and IMRT. Based on this result, compared with IMRT, SBRT was considered cost-effective. The authors performed a sensitivity analysis and the sensitivity analysis indicated that if the SBRT cohort experienced a decrease in quality of life of 4% or a decrease in efficacy of 6%, then SBRT would no longer dominate IMRT in cost-effectiveness \[[@CR19]\]. This sensitivity analysis also indicated that the ICER for SBRT over IMRT was less than \$50,000/QALY in 66% of the sensitivity analysis scenarios.Table 4Main findings of Cost-effectiveness studies comparing IMRT, SBRT and PBT for localized prostate cancerStudy (authors, year)ResultConclusionsMean costQALYsICERHodges et al. (2012) \[[@CR19]\]SBRT: \$22,152IMRT: \$35,431SBRT = 7.9IMRT = 7.9NA"Compared with IMRT, SBRT for low- to intermediate-risk prostate cancer has great potential cost savings"Sher et al. (2014) \[[@CR20]\]IMRT: \$27,564Non-robotic SBRT: \$10,108Cyber-knife SBRT: \$19,275IMRT: 9.96SBRT: 9.93IMRT vs robotic SBRT: \$285,000/QALYIMRT vs Non- robotic: US\$591,100/QALY"SBRT clearly contained more value than IMRT for external-beam treatment"Parthan et al. (2012) \[[@CR18]\]Payer perspectiveIMRT: \$33,068PBT: \$69,412SBRT: \$24,873Societal perspectiveSBRT: \$25,097, IMRT: \$35,088 PBT: \$71,657SBRT: 8.11IMRT: 8.05PBT: 8.06SBRT was dominating over RT and IMRT (less costly and more QALYs)"Based on the assumption that each treatment modality results in equivalent long-term efficacy, SBRT is a cost-effective strategy resulting in improved quality-adjusted survival compared to IMRT and PT for the treatment of localized prostate cancer"Lundkvist, et al. (2005) \[[@CR21]\]Proton: €13,491IMRT: €5477CostStandard case result: 7952.6High proton radiation cost estimate: 10,485.2Low proton radiation cost estimate: 7343.9QALYStandard case result: 0.297High proton radiation cost estimate: 0.297Low proton radiation cost estimate: 0.297"Investment in a proton facility may thus be cost-effective. The results must be interpreted with caution, since there is a lack of data, and consequently large uncertainties in the assumptions used"Konski et al. (2007) \[[@CR22]\]70-year-old manPBT: \$63,511 IMRT: \$36,80860-year-old manPBT: \$64,989 IMRT: \$39,35570-year-old manPBT: 8.54IMRT: 8.1260-year-old manPBT: 9.91IMRT: 9.4570-year-old man\$63,578/QALY60-year-old man\$55,726/QALY"Even when based on the unproven assumption that protons will permit a 10-Gy escalation of prostate dose compared with IMRT photons, proton beam therapy is not cost effective for most patients with prostate cancer using the commonly accepted standard of \$50,000/QALY"

On the other hand, the cost effectiveness analysis by Sher et al. \[[@CR20]\] found that the cost of IMRT, non-robotic SBRTand Cyber-knife SBRT were \$27,564, \$10,108 and \$19,275 respectivelly. The QALY for IMRT (9.96) was slightly higher than after SBRT (9.93) under the assumption of worse toxicity after SBRT \[[@CR20]\]. The ICER for IMRT over robotic SBRT and non-robotic SBRT were US\$285,000 and US\$591,100/QALY, respectively. The authors concluded that SBRT clearly contained more value than IMRT for external-beam treatment. After the sensitivity analysis SBRT was almost always the cost-effective therapy, in which the ICER for IMRT was generally over \$100,000/QALY. Reimbursement for Robotic-SBRT versus non-robotic -SBRT significantly influenced its ICER. Treatment efficacy, rectal toxicity and impotence, and the potential for unforeseen SBRT late effects were the most critical parameters in the model; when including these uncertain parameters in a PSA, SBRT was still most likely to be cost-effective at a willingness to pay of \$100,000/QALY.

Parthan et al. \[[@CR18]\] compared three external beam radiation therapy alternatives and their result showed that compared to IMRT and PBT, SBRT was less costly and resulted in more QALYs. The authors conducted their analysis both from the payer's and societal perspective. From the payer's perspective the life time cost of SBRT, IMRT and PBT were \$24,873, \$33,068 and \$69,412 respectively. Whereas, from the societal perspective where the lost work time was calculated, the life time costs were \$25,097, \$35,088 and \$71,657 respectively. In both perspectives the authors found that SBRT was the least expensive. The QALYs for SBRT, IMRT and PBT were 8.11, 8.06, and 8.05 respectively. The authors performed a sensitivity analysis and the conclusions in the base-case scenario were robust with respect to variations in toxicity and cost parameters consistent with available evidence \[[@CR18]\]. The authors showed that from the payer's perspective, at a threshold of \$50,000/QALY, SBRT was cost-effective in 75% and 94% of probabilistic simulations compared to IMRT and PT, respectively. From a societal perspective, SBRT was cost-effective in 75% and 96% of simulations compared to IMRT and PT, respectively, at a threshold of \$50,000/QALY. In threshold analyses, SBRT was less expensive with better outcomes compared to IMRT at toxicity rates 23% greater than the SBRT base-case rates. In general, the authors concluded that SBRT was cost-effective, resulting in cost savings and improved QALYs compared to IMRT and PBT for the treatment of localized prostate cancer. From the above studies that compared IMRT, SBRT and PBT in all studies SBRT was found to be cost effective.

Lundkvist et al. \[[@CR21]\] assessed the cost-effectiveness of proton therapy compared with IMRT for different cancer types including left-sided breast cancer, prostate cancer, head and neck cancer, and childhood medulloblastoma. The study assumed that 300 prostate cancer patients per year would be treated with proton therapy. The study found that the total radiation cost for prostate cancer was €5477 and the cost of proton was estimated €13,491. The average cost per QALY gained for the standard case was about €7952.6 with the total numbers of gained QALYs were calculated to 0.30. The study concluded that investment in proton facility is cost-effective. However, the cost effectiveness of proton facility depends on the total cancer patients treated since the authors studied several types of cancer.

The analysis by Konski et al. \[[@CR22]\] found that the expected mean cost of for a time horizon of 15 years for proton beam therapy and IMRT of \$63,511 and \$36,808, and \$64,989 and \$39,355 for a 70-year-old and 60-year-old man respectively, with quality-adjusted survival of 8.54 and 8.12 and 9.91 and 9.45 QALY, respectively. The incremental cost effectiveness ratio was calculated to be \$63,578/QALY for a 70-year-old man and \$55,726/QALY for a 60-year-old man. The authors performed sensitivity analysis and showed that the probability of cost effectiveness increases as the willingness to pay increases. The probability of cost effectiveness is 49% at a willingness to pay of \$50,000/quality-adjusted life-year.

The critical appraisal of the included studies according to Drummond's 10 item check list is illustrated in Additional file [1](#MOESM1){ref-type="media"}: Appendix S3. From the included 12 economic evaluations, 10 studies scored ≥ 9 points. Two studies \[[@CR16], [@CR21]\] scored 5 points. The items that most frequently failed was about effectiveness. Out of 12 studies, 8 studies do not satisfy the conditions for program effectiveness.

Discussion and conclusion {#Sec9}
=========================

In this systematic review, 12 studies were identified that investigated the cost effectiveness of different external beam radiation therapy options for the treatment of localized prostate cancer. Mainly there were four treatment modalities included in the review. These are three-dimensional conformal radiation therapy (3D-CRT), intensity modulated radiation therapy (IMRT), stereotactic body radiation therapy (SBRT) and proton beam radiation therapy (PBR). Articles published between 2003 and 2017 that conducted full-economic evaluations were included in the review. From 12 articles 7 studies were compared the cost effectiveness of IMRT with 3D-CRT \[[@CR11]--[@CR17]\]), one article compared three external beam radiation therapy of IMRT, SBRT and PBT \[[@CR18]\] and two article compared IMRT with SBRT \[[@CR19], [@CR20]\]. The other two articles \[[@CR21], [@CR22]\] were compared the cost effectiveness of IMRT with PBT for the treatment of prostate cancer.

For most of the studies the target population of the analysis were those men with prostate cancer aged above 65 years and 70 years. This shows that Prostate cancer affect most of the older population. Most of the studies were conducted from the US and from the health care payer perspective. The result of most of the studies indicated that IMRT was found to be cost-effective when it is compared with 3D-CRT. Cartel et al. \[[@CR11]\] showed that IMRT was a dominant strategy. On the other way SBRT was found to be cost effective when compared with IMRT.

There are limited number of studies exist on the cost effectiveness of radiation therapy options for the treatment of localize prostate cancer across Europe. Most studies are originated from the US Medicare payer Perspective. Further research is need that investigate the cost effectiveness of these radiation therapy options from the societal perspective in Europe. Evidence base cost effectiveness studies based on market demand for medical services remain significant for future studies especially in larger society settings.

Additional file
===============

 {#Sec10}

**Additional file 1: Appendix S1.** Search strings used for systematic search of economic evaluations of prostate cancer. **Appendix S2**. Patient Intervention Comparator Outcome (PICO) strategy. **Appendix S3**. Critical Appraisal of the selected published literatures for systematic review.

2-DRT

:   two-dimensional radiotherapy

3D-CRT

:   three-dimensional conformal radiotherapy

ICER

:   incremental cost effectiveness ratio

IMRT

:   intensity-modulated radiation therapy

EBRT

:   external beam radiotherapy

GI

:   gastrointestinal

ISPOR

:   International Society for Pharmacoeconomics and Outcomes Research ISPOR

LE

:   life expectancy

NHS EED

:   National Health System Economic Evaluation Database

PBT

:   proton beam therapy

PRISMA

:   preferred reporting items for systematic reviews and meta-analyses

QALYs

:   quality-adjusted life years

RCT

:   randomized control trial

SBRT

:   stereotactic body radiation therapy

UK

:   United Kingdom

US

:   United States
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